V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210028178 | 210022676 | null | 17.2 | Palliative (P) | 2016-01-05 | 2016-01-11 | CNS LGG Irinotecan & Bevacizumab | 02 | null | 210034103 | FLAG |
| 210028179 | 210013910 | 0 | null | Disease modification (D) | 2017-11-16 | 2017-11-23 | CARBO + ETOPOSIDE + VINCRISTINE | N | N | 210034192 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE + METHOTREXATE |
| 210028180 | 210033721 | 0 | 74.4 | Palliative (P) | 2019-09-08 | 2019-09-23 | STS Rhabdomyosarcoma RMS 2005 IVADo | N | N | 210034315 | CLARITY TRIAL |
| 210028181 | 210013913 | 1.65 | 28 | Curative (C) | 2017-02-10 | 2017-06-14 | Cladribine + Rituximab | 2 | N | 210034377 | ALL MAINTENANCE |
| 210028182 | 210013914 | 1.82 | 117.5 | Curative (C) | 2016-05-18 | 2016-05-18 | NHL 2003 Gp C M1 | N | N | 210034385 | DOCETAXEL |
| 210028183 | 210013916 | 1.59 | 68.6 | Curative (C) | 2018-10-04 | 2018-11-12 | THIOTEPA | N | N | 210034391 | CLL210 TRIAL |
| 210028184 | 210022684 | 1.62 | 99.7 | Disease modification (D) | 2017-02-15 | 2017-02-15 | CYCLOPHOSPHAMIDE + ETOPOSIDE + NELARABINE | 2 | N | 210034477 | MITOMYCIN |
| 210028185 | 210013921 | 1.74 | null | null | 2018-03-26 | 2018-03-26 | CLL210 TRIAL | 2 | N | 210034639 | UKALL2003 |
| 210028186 | 210013922 | 1.43 | 84 | Disease modification (D) | 2015-09-12 | 2015-09-15 | Hydroxycarbamide | N | N | 210034650 | IRINOTECAN + MDG |
| 210028187 | 210013923 | null | 81.8 | Palliative (P) | 2018-04-25 | 2018-04-26 | FCR IV - Cycle 2 onwards | 2 | N | 210034878 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 210028188 | 210022688 | 1.69 | 52.3 | Curative (C) | 2014-10-06 | 2014-10-10 | IVAC | 2 | N | 210034999 | UKALL 60+ TRIAL |
| 210028189 | 210013926 | null | 75.6 | Palliative (P) | 2015-10-19 | 2015-10-28 | BR14 TRIAL | null | N | 210035018 | CYCLOPHOSPHAMIDE + ETOPOSIDE + NELARABINE |
| 210028190 | 210013928 | 1.66 | 95.6 | Palliative (P) | 2018-02-04 | 2018-02-04 | DAUNORUBICIN + VINCRISTINE | N | N | 210035172 | MELPHALAN |
| 210028191 | 210028231 | null | null | Disease modification (D) | 2018-03-21 | 2018-03-27 | ALL UKALL2003 C: Ph VII Maintenance | 2 | Y | 210035201 | AML19 TRIAL |
| 210028192 | 210013935 | null | 82.2 | null | 2016-04-16 | 2019-03-20 | IMMUNOGLOBULIN | N | N | 210035396 | DAUNORUBICIN |
| 210028193 | 210033722 | 1.86 | 83.7 | Curative (C) | 2017-06-21 | 2017-06-21 | CYCLOPHOSPHAMIDE + THALIDOMIDE | N | null | 210035468 | CLL210 TRIAL |
| 210028194 | 210013938 | 1.68 | null | Palliative (P) | 2015-09-25 | 2016-10-23 | MITOMYCIN | 2 | N | 210035508 | ALEMTUZUMAB + CYCLO + FLUDARABINE |
| 210028195 | 210013939 | 1.73 | null | Palliative (P) | 2016-08-14 | 2016-08-22 | CARBOPLATIN + Procarbazine | N | N | 210035520 | THALIDOMIDE |
| 210028196 | 210013939 | 1.82 | 78.4 | Palliative (P) | null | 2016-06-20 | Doxorubicin + Ifosfamide | null | Y | 210035520 | CVD |
| 210028197 | 210013942 | 1.71 | 8.8 | Not known (9) | 2018-01-25 | 2018-01-26 | Cyclophosphamide High Dose | null | null | 210035566 | CLARITY TRIAL |
| 210028198 | 210013944 | 1.6 | 89.5 | null | 2018-07-28 | 2018-07-29 | Fludarabine (po) + Rituximab | N | N | 210035730 | MELPHALAN |
| 210028199 | 210013947 | 1.64 | 50 | Curative (C) | 2016-04-20 | 2016-04-21 | ALL UKALL2003 C: Ph VII Maintenance | 02 | N | 210036052 | CLL210 TRIAL |
| 210028200 | 210013949 | 1.6 | null | Curative (C) | 2013-11-18 | 2014-02-11 | Docetaxel 75mg/m2 (21 day) | N | null | 210036092 | LENALIDOMIDE + RITUXIMAB |
| 210028201 | 210031599 | null | 18.1 | null | 2015-08-18 | 2015-08-26 | Cyclophosphamide High Dose | null | null | 210036240 | FLUDARABINE |
| 210028202 | 210031599 | 1.77 | 80 | null | 2017-11-06 | 2017-11-09 | Bevacizumab+temoz+RT (weeks 1 to 6) | 02 | N | 210036240 | CYTARABINE IT + METHOTREXATE |
| 210028203 | 210013951 | 1.72 | 46.3 | Curative (C) | 2017-08-28 | 2017-08-28 | Cytarabine intrathecal | N | N | 210036418 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE + METHOTREXATE |
| 210028204 | 210022702 | 1.72 | 87.6 | Disease modification (D) | 2017-07-09 | 2017-07-16 | CLL210 TRIAL | 1 | N | 210036454 | CYCLO + FLUDARABINE + RITUXIMAB |
| 210028205 | 210013954 | 1.59 | 55.2 | Disease modification (D) | 2014-08-11 | 2014-10-04 | CLOFARABINE + CYCLOPHOSPHAMIDE + ETOPOSIDE | 1 | N | 210036485 | PEMBROLIZUMAB |
| 210028206 | 210013958 | 1.64 | 75.2 | Disease modification (D) | 2019-09-22 | 2019-10-03 | Ofatumumab Weekly | N | null | 210036496 | CLARITY TRIAL |
| 210028207 | 210031601 | 1.53 | 68.6 | null | 2019-01-31 | 2019-02-18 | Ofatumumab Weekly | N | N | 210036578 | ALL |
| 210028208 | 210022709 | 1.79 | 95.5 | Curative (C) | null | 2015-07-23 | DABRAFENIB + TRAMETINIB | N | N | 210036643 | CYCLOPHOSPHAMIDE + ETOPOSIDE + PROCARBAZINE |
| 210028209 | 210013967 | null | 112.8 | Curative (C) | null | 2018-01-26 | CARBO + ETOPOSIDE + VINCRISTINE | 02 | null | 210036864 | LENALIDOMIDE |
| 210028210 | 210013968 | null | 85 | Curative (C) | 2017-01-25 | 2017-01-30 | ALL UKALL2003 C: Ph VII Maintenance | null | N | 210036881 | CYTARABINE HD + METHOTREXATE HD |
| 210028211 | 210013969 | 1.55 | null | null | 2018-12-16 | 2019-01-28 | Hydroxycarbamide | 02 | N | 210036916 | FLAG |
| 210028212 | 210013970 | 1.7 | 61.6 | Disease modification (D) | 2014-02-26 | 2014-04-02 | Cytarabine HD + Methotrexate HD | 02 | N | 210036941 | ABIRATERONE |
| 210028213 | 210013972 | 1.83 | null | Curative (C) | 2016-10-21 | 2016-10-21 | AML 19 TRIAL | N | N | 210037146 | OFATUMUMAB |
| 210028214 | 210013975 | 1.82 | null | Disease modification (D) | 2013-10-29 | 2013-10-29 | Erlotinib | N | N | 210037309 | MACE |
| 210028215 | 210013976 | 1.57 | 28 | Palliative (P) | 2016-06-12 | 2016-06-27 | Cyclophosphamide High Dose | 02 | N | 210037404 | ABIRATERONE |
| 210028216 | 210028244 | 1.67 | 42.2 | Curative (C) | 2014-10-25 | 2014-10-29 | CARBOPLATIN + VINORELBINE | 02 | null | 210037481 | ABVD |
| 210028217 | 210013978 | 1.77 | null | Curative (C) | 2018-01-19 | 2018-11-01 | Fludarabine IV | N | N | 210037672 | LENALIDOMIDE + RITUXIMAB |
| 210028218 | 210013980 | null | 85.6 | Palliative (P) | 2019-05-03 | 2019-05-10 | FLUDARABINE | N | null | 210037675 | CAPECITABINE |
| 210028219 | 210031605 | 1.63 | 82.3 | Curative (C) | 2018-08-11 | 2018-08-16 | CYTARABINE | N | null | 210037833 | IMMUNOGLOBULIN |
| 210028220 | 210013985 | 1.59 | null | Disease modification (D) | 2018-03-31 | 2018-04-27 | Packer Maintenance Regimen | null | N | 210037888 | CVD |
| 210028221 | 210013986 | 1.76 | 102 | Curative (C) | 2017-11-25 | 2017-11-25 | CLARITY Trial | null | N | 210038079 | UKALL2003 |
| 210028222 | 210013990 | null | 16.8 | Palliative (P) | 2016-03-31 | 2016-11-01 | Packer Maintenance Regimen | null | N | 210038210 | CLARITY TRIAL |
| 210028223 | 210013993 | 1.69 | 47 | Curative (C) | 2017-03-05 | 2017-03-29 | Maintenance Therapy ALL | N | N | 210038619 | CAV |
| 210028224 | 210013995 | 1.64 | 26.8 | Curative (C) | 2017-11-01 | 2018-08-02 | Packer Maintenance Regimen | 2 | N | 210038641 | UKALL2003 |
| 210028225 | 210013995 | 1.62 | 68.6 | null | 2017-09-17 | 2017-10-14 | Docetaxel 100mg/m2 (21 day) | N | Y | 210038641 | CODOX M |
| 210028226 | 210013999 | null | 49.7 | Disease modification (D) | 2017-03-04 | 2017-06-02 | AML 19 TRIAL | null | N | 210038854 | CYCLO + FLUDARABINE + RITUXIMAB |
| 210028227 | 210014001 | null | 48.1 | Palliative (P) | 2017-12-16 | 2017-12-16 | CYTARABINE | N | N | 210038863 | FLUOROURACIL |